Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions

被引:46
作者
Akshintala, Srivandana [1 ]
Baldwin, Andrea [1 ]
Liewehr, David J. [2 ]
Goodwin, Anne [1 ]
Blakeley, Jaishri O. [3 ]
Gross, Andrea M. [1 ]
Steinberg, Seth M. [2 ]
Dombi, Eva [1 ]
Widemann, Brigitte C. [1 ]
机构
[1] NC, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20814 USA
[2] NCI, Ctr Canc Res, NIH, Bethesda, MD 20814 USA
[3] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA
关键词
atypical neurofibroma; neurofibromatosis; plexiform neurofibroma; volumetric MRI; ATYPICAL NEUROFIBROMAS; CLINICAL-TRIALS; CHILDREN; BENIGN; MRI; VOLUME;
D O I
10.1093/neuonc/noaa053
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Understanding the natural history of non-malignant peripheral nerve sheath tumors (PNSTs) in neurofibromatosis type 1 (NH) is critical to optimal clinical care and the development of meaningful clinical trials. Methods. We longitudinally analyzed growth of plexiform neurofibromas (PNs) and of PNSTs with distinct nodular appearance (distinct nodular lesions [DNLs]) using volumetric MRI analysis in patients enrolled on a natural history study (NCT00924196). Results. DNLs were observed in 58/122 (45.6%) patients (median 2 DNLs/patient). In DNLs that developed during follow-up, median age of development was 17 years. A moderate negative correlation was observed between the estimated PN growth rate and patients' age at initial MRI (Spearman's r [95% CI]: -0.60 [-0.73, -0.43], n = 70), whereas only a weak correlation was observed for DNLs (Spearman's r [95% CI]: -0.25 [-0.47, 0.004]; n = 61). We observed a moderate negative correlation between tumor growth rate and baseline tumor volume for PNs and DNLs (Spearman's r [95% CI]: -0.52 [-0.67, -0.32] and -0.61 [-0.75, -0.42], respectively). Spontaneous tumor volume reduction was observed in 10 PNs and 7 DNLs (median decrease per year, 3.6% and 7.3%, respectively). Conclusion. We corroborate previously described findings that most rapidly growing PNs are observed in young children. DNLs tend to develop later in life and their growth is minimally age related. Distinct growth characteristics of PNs and DNLs suggest that these lesions have a different biology and may require different clinical management and clinical trial design. In a subset of PNs and DNLs, slow spontaneous regression in tumor volume was seen.
引用
收藏
页码:1368 / 1378
页数:11
相关论文
共 28 条
[1]   Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2 [J].
Abaza, MM ;
Makariou, E ;
Armstrong, M ;
Lalwani, AK .
LARYNGOSCOPE, 1996, 106 (06) :694-699
[2]   Atypical Neurofibromas in Neurofibromatosis Type 1 are Premalignant Tumors [J].
Beert, Eline ;
Brems, Hilde ;
Daniels, Bruno ;
De Wever, Ivo ;
Van Calenbergh, Frank ;
Schoenaers, Joseph ;
Debiec-Rychter, Maria ;
Gevaert, Olivier ;
De Raedt, Thomas ;
Van den Bruel, Annick ;
de Ravel, Thomy ;
Cichowski, Karen ;
Kluwe, Lan ;
Mautner, Victor ;
Sciot, Raf ;
Legius, Eric .
GENES CHROMOSOMES & CANCER, 2011, 50 (12) :1021-1032
[3]   Resection of Plexiform Neurofibromas in Children With Neurofibromatosis Type 1 [J].
Canavese, Federico ;
Krajbich, Joseph I. .
JOURNAL OF PEDIATRIC ORTHOPAEDICS, 2011, 31 (03) :303-311
[4]   NF1 plexiform neurofibroma growth rate by volumetric MRI - Relationship to age and body weight [J].
Dombi, E. ;
Solomon, J. ;
Gillespie, A. J. ;
Fox, E. ;
Balis, F. M. ;
Patronas, N. ;
Korf, B. R. ;
Babovic-Vuksanovic, D. ;
Packer, R. J. ;
Belasco, J. ;
Goldman, S. ;
Jakacki, R. ;
Kieran, M. ;
Steinberg, S. M. ;
Widemann, B. C. .
NEUROLOGY, 2007, 68 (09) :643-647
[5]   Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas [J].
Dombi, Eva ;
Baldwin, Andrea ;
Marcus, Leigh J. ;
Fisher, Michael J. ;
Weiss, Brian ;
Kim, AeRang ;
Whitcomb, Patricia ;
Martin, Staci ;
Aschbacher-Smith, Lindsey E. ;
Rizvi, Tilat A. ;
Wu, Jianqiang ;
Ershler, Rachel ;
Wolters, Pamela ;
Therrien, Janet ;
Glod, John ;
Belasco, Jean B. ;
Schorry, Elizabeth ;
Brofferio, Alessandra ;
Starosta, Amy J. ;
Gillespie, Andrea ;
Doyle, Austin L. ;
Ratner, Nancy ;
Widemann, Brigitte C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (26) :2550-2560
[6]   Recommendations for imaging tumor response in neurofibromatosis clinical trials [J].
Dombi, Eva ;
Ardern-Holmes, Simone L. ;
Babovic-Vuksanovic, Dusica ;
Barker, Fred G. ;
Connor, Steve ;
Evans, D. Gareth ;
Fisher, Michael J. ;
Goutagny, Stephane ;
Harris, Gordon J. ;
Jaramillo, Diego ;
Karajannis, Matthias A. ;
Korf, Bruce R. ;
Mautner, Victor ;
Plotkin, Scott R. ;
Poussaint, Tina Y. ;
Robertson, Kent ;
Shih, Chie-Schin ;
Widemann, Brigitte C. .
NEUROLOGY, 2013, 81 (21) :S33-S40
[7]  
Fisher M, 2018, 2018 JOINT GLOB NEUR
[8]   Optimizing biologically targeted clinical trials for neurofibromatosis [J].
Gutmann, David H. ;
Blakeley, Jaishri O. ;
Korf, Bruce R. ;
Packer, Roger J. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (04) :443-462
[9]   The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors [J].
Higham, Christine S. ;
Dombi, Eva ;
Rogiers, Aljosja ;
Bhaumik, Sucharita ;
Pans, Steven ;
Connor, Steve E. J. ;
Miettinen, Markku ;
Sciot, Raf ;
Tirabosco, Roberto ;
Brems, Hilde ;
Baldwin, Andrea ;
Legius, Eric ;
Widemann, Brigitte C. ;
Ferner, Rosalie E. .
NEURO-ONCOLOGY, 2018, 20 (06) :818-825
[10]   Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas [J].
Kim, A. ;
Gillespie, A. ;
Dombi, E. ;
Goodwin, A. ;
Goodspeed, W. ;
Fox, E. ;
Balis, F. M. ;
Widemann, B. C. .
NEUROLOGY, 2009, 73 (16) :1273-1279